Targeted Lipid Technology

The combination of a protected blood transporting nanocarrier system and a specific activation technology makes LiPlasome Pharma very competitive in a commercially attractive anticancer market, where drug delivery systems (DDS) will gain increasing importance in the coming years. This is due to its potential to increase the effect of existing anti cancer agents and at the same time reduce their side effects.

LiPlasome Pharma’s proprietary drug delivery technology represents a spin-off from research performed at DTU (The Danish Technical University).